Clinical efficacy of fractional carbondioxide laser combined with tacrolimus ointment in treatment of localized vitiligo / 吉林大学学报(医学版)

ABSTRACT

Objective: To compare the curative effects and adverse reactions of fractional carbondioxide laser combined with tacrolimus ointment and tacrolimus ointment alone in the treatment of localized vitiligo, and to evaluate their safeties. Methods: The clinical materials of 98 patients with localized vitiligo were retrospectively analyzed. The patients were divided into two groups according to their wishes. The patients in control group (47 cases) were treated with tacrolimus ointment every morning and evening only, and the patients in observation group (51 cases) were treated with fractional carbondioxide laser combined with tacrolimus ointment and the laser was used once every 4 weeks. The treatment lasted for 12 weeks. Compound Glycyrrhizin Tablets were used according to the conditions (3 pieces each time, 3 times a day, a total of 12 weeks). The follow-up period was once every 2 weeks. The clinical efficacy and adverse reactions of the patients in two groups were assessed in the 12th weeks after treatment. Results: The onset time of treatment of the patients in observation group was shorter than that in control group (t=13. 82, P=0. 001), and the total effective rate of the patients in observation group was higher than that in control group (χ2 = 4. 72, P<0. 05). The effective rates of the faciocervical lesion of the patients in observation group and control group were higher than those of the trunk lesion (χ2 = 23. 78, P<0. 05; % = 12. 79, P<0. 05). The effective rate of the faciocervical lesion of the patients in observation group was higher than that in control group (χ2= 5.75, P< 0. 05); there were no serious adverse reactions in all patients. Conclusion: The combination of fractional carbondioxide laser and tacrolimus ointment in the treatment of localized vitiligo has the advantages of quick effect, good efficacy and high safety, and is worthy of clinical application.